AbbVie (ABBV) vs Abbott Laboratories (ABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbbVie (ABBV) has outperformed Abbott Laboratories (ABT) over the past year, gaining 16.5% versus a loss of 25.8%. Over five years, ABBV leads with a +148.2% price change compared with -16.0% for ABT. AbbVie is the larger company by market cap ($479.52 billion vs $170.84 billion), about 2.8 times the size.
On valuation, Abbott Laboratories trades at a lower forward P/E (16.3x vs 16.7x for AbbVie). AbbVie offers the higher dividend yield (2.52% vs 2.51%). Abbott Laboratories converts more of its revenue into profit, with a net margin of 14.7% versus 6.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABBV | ABT |
|---|---|---|
| Share price | $271.36 | $98.73 |
| Market cap | $479.52B | $170.84B |
| 1-day change | +1.75% | +0.58% |
| YTD return | +18.76% | -21.20% |
| 1-year return | +16.55% | -25.78% |
| 5-year return | +148.20% | -15.97% |
| P/E ratio (TTM) | 76.66 | 31.64 |
| Forward P/E | 16.69 | 16.28 |
| EPS (TTM) | $3.54 | $3.12 |
| Dividend yield | 2.52% | 2.51% |
| Annual dividend | $6.83 | $2.48 |
| Revenue (latest FY) | $61.16B | $44.33B |
| Revenue growth (YoY) | +8.57% | +5.67% |
| Net income (latest FY) | $4.23B | $6.52B |
| Gross margin | 70.24% | 56.42% |
| Operating margin | 24.65% | 18.17% |
| Net margin | 6.91% | 14.72% |
| 52-week high | $274.94 | $135.13 |
| 52-week low | $190.75 | $81.97 |
| Distance from 52-week high | -1.30% | -26.94% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +3.48% | +22.27% |
| Average volume | 4.86M | 9.56M |
| Shares outstanding | 1.77B | 1.73B |
| Employees | 57,000 | 122,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AbbVie is about 2.8 times larger than Abbott Laboratories by market value ($479.52B vs $170.84B).
- ABBV has outperformed ABT by 42.3 percentage points over the past year.
- AbbVie trades at a higher earnings multiple (76.7x vs 31.6x trailing P/E).
- Abbott Laboratories is more profitable, keeping 14.7 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
About AbbVie
ABBV stock →AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees
About Abbott Laboratories
ABT stock →Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Health Care · Biotechnology: Pharmaceutical Preparations · 122,000 employees
ABBV vs ABT FAQ
Which is bigger, AbbVie or Abbott Laboratories?
AbbVie (ABBV) is larger, with a market capitalization of $479.52B compared with $170.84B for Abbott Laboratories (ABT).
Which stock has performed better over the past year, ABBV or ABT?
ABBV returned +16.55% over the past 12 months, compared with -25.78% for ABT (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABBV or ABT?
ABT has the lower trailing P/E at 31.6, versus 76.7 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AbbVie or Abbott Laboratories?
AbbVie has the higher yield at 2.52%, compared with 2.51% for Abbott Laboratories.
Are AbbVie and Abbott Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.